EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Improved endurance capacity of diabetic mice during SGLT2 inhibition: Role of AICARP, an AMPK activator in the soleus

Shintaro Nakamura, Yasutaka Miyachi iD, Akihito Shinjo, Hisashi Yokomizo, Masatomo Takahashi, Kohta Nakatani, Yoshihiro Izumi, Hiroko Otsuka, Naoichi Sato, Ryuichi Sakamoto, Takashi Miyazawa, Takeshi Bamba und 1 weitere

Journal of Cachexia, Sarcopenia and Muscle · 2023-12 · 14 (6) · 2866-2881

DOI: 10.1002/jcsm.13350 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, online erschienen am 08.11.2023. Verfasst von Shintaro Nakamura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Mitsui Sumitomo Insurance Welfare Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetes is associated with an increased risk of deleterious changes in muscle mass and function or sarcopenia, leading to physical inactivity and worsening glycaemic control. Given the negative energy balance during sodium–glucose cotransporter‐2 (SGLT2) inhibition, whether SGLT2 inhibitors affect skeletal muscle mass and function is a matter of concern. However, how SGLT2 inhibition affects the skeletal muscle function in patients with diabetes remains insufficiently explored. We aimed to explore the effects of canagliflozin (CANA), an SGLT2 inhibitor, on skeletal muscles in genetically diabetic db/db mice focusing on the differential responses of oxidative and glycolytic muscles.

Methods

Db / db mice were treated with CANA for 4 weeks. We measured running distance and handgrip strength to assess skeletal muscle function during CANA treatment. At the end of the experiment, we performed a targeted metabolome analysis of the skeletal muscles.

Results

CANA treatment improved the reduced endurance capacity, as revealed by running distance in db / db mice (414.9 ± 52.8 vs. 88.7 ± 22.7 m, P < 0.05). Targeted metabolome analysis revealed that 5‐aminoimidazole‐4‐carboxamide‐1‐β‐D‐ribofuranosyl 5′‐monophosphate (AICARP), a naturally occurring AMP‐activated protein kinase (AMPK) activator, increased in the oxidative soleus muscle ( P < 0.05), but not in the glycolytic extensor digitorum longus muscle ( P = 0.4376), with increased levels of AMPK phosphorylation ( P < 0.01).

Conclusions

This study highlights the potential role of the AICARP/AMPK pathway in oxidative rather than glycolytic skeletal muscles during SGLT2 inhibition, providing novel insights into the mechanism by which SGLT2 inhibitors improve endurance capacity in patients with type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsAnimalsHumansMiceAMP-Activated Protein KinasesHand StrengthMuscle, SkeletalSodium-Glucose Transporter 2

Stichwörter der Autor:innen

AICARPAMPKSGLT2 inhibitorendurance exercisefatty acid oxidationskeletal muscle

Substanzen

AMP-Activated Protein KinasesSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Division of Metabolomics/Mass Spectrometry Center, Medical Research Center for High Depth Omics, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.

ORCID-Profile: Yasutaka Miyachi

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development
  • Mitsui Sumitomo Insurance Welfare Foundation
  • Mitsubishi Tanabe Pharma Corporation
  • Takeda Science Foundation

Zitieren

APA

Nakamura, S., Miyachi, Y., Shinjo, A., Yokomizo, H., Takahashi, M., Nakatani, K., Izumi, Y., Otsuka, H., Sato, N., Sakamoto, R., Miyazawa, T., Bamba, T., & Ogawa, Y. (2023). Improved endurance capacity of diabetic mice during SGLT2 inhibition: Role of AICARP, an AMPK activator in the soleus. Journal of Cachexia, Sarcopenia and Muscle, 14(6), 2866-2881. https://doi.org/10.1002/jcsm.13350

Vancouver

Nakamura S, Miyachi Y, Shinjo A, Yokomizo H, Takahashi M, Nakatani K, et al. Improved endurance capacity of diabetic mice during SGLT2 inhibition: Role of AICARP, an AMPK activator in the soleus. Journal of Cachexia, Sarcopenia and Muscle. 2023;14(6):2866-2881. doi:10.1002/jcsm.13350

BibTeX
@article{Nakamura2023,
  author = {Nakamura, Shintaro and Miyachi, Yasutaka and Shinjo, Akihito and Yokomizo, Hisashi and Takahashi, Masatomo and Nakatani, Kohta and Izumi, Yoshihiro and Otsuka, Hiroko and Sato, Naoichi and Sakamoto, Ryuichi and Miyazawa, Takashi and Bamba, Takeshi and Ogawa, Yoshihiro},
  title = {Improved endurance capacity of diabetic mice during SGLT2 inhibition: Role of AICARP, an AMPK activator in the soleus},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2023},
  volume = {14},
  number = {6},
  pages = {2866--2881},
  doi = {10.1002/jcsm.13350}
}
Kostenlos starten →